

Review

The transcription factor *Fos*: a Janus-type regulator in health and disease

Moritz Durchdewald, Peter Angel and Jochen Hess

German Cancer Research Center (DKFZ), DKFZ-ZMBH Alliance, Division of Signal Transduction and Growth Control, Heidelberg, Germany

Summary. The immediate early gene product *Fos* is part of the activator protein-1 (AP-1) transcription factor and has been shown to participate in the molecular mechanisms of cell proliferation, differentiation, apoptosis, and transformation. The analysis of genetically modified mice and cells derived thereof has provided important new insights into its specific biological functions in development, tissue homeostasis, and cellular responses to environmental insults. Moreover, the deregulation of *Fos* could be linked with a variety of pathological conditions, including immunological, skeletal and neurological defects, as well as oncogenic transformation and tumor progression. In contrast to the mainstream opinion concerning the oncogenic function of *Fos* an increasing number of experimental reports also describe a tumor-suppressive function in various cancer types. More recently, altered *Fos* expression in cell culture and mouse models combined with global gene expression analysis unraveled novel downstream effectors of the *Fos*-regulated genetic program. Finally, selective inhibition of its function with a small molecule inhibitor in a preclinical mouse model of arthritis demonstrated that targeting *Fos*/AP-1 activity could be an auspicious new option for clinical use.

Key words: AP-1, Bone, Cancer, CNS, Oncogene

Introduction

Fos was initially identified as a viral oncogene (*v-Fos*) from murine osteosarcomas whose expression resulted in cell transformation (Curran et al., 1983; Van Beveren et al., 1983; Angel and Karin, 1991). The cellular *Fos* homologue (also known as *c-Fos*) was among the first immediate early genes to be identified and shares all characteristics of this group of genes: (i) low or undetectable expression in quiescent cells, but rapid transcription in response to many extracellular signals, (ii) transcriptional induction is transient and independent of new protein synthesis, and (iii) specific transcript with very a short half-life that encodes a protein with high turnover. The *Fos* protein preferentially forms heterodimers with members of the Jun protein family (Jun, Junb, Jund) to acquire transcriptional competence (Angel and Karin, 1991; Shaulian and Karin, 2002). As *Fos*/Jun heterodimeric complexes recognize the so-called TPA-responsive element (TRE = TGA^G/C/TCA) that is found in the regulatory units of many genes, *Fos* is involved in the regulation of a large variety of physiological processes. At the cellular level, *Fos* regulates proliferation, differentiation, cell death, and response to environmental cues, and in organisms *Fos* plays paramount roles in organogenesis, immune response, congenital functions, among others (Wagner, 2001; Eferl and Wagner, 2003; Hess et al., 2004).

The *Fos* gene is subjected to complex regulation at multiple interwoven transcriptional and post-transcriptional levels, which is necessary to avoid, or at least limit, pathological effects caused by its deregulation (Shaulian and Karin, 2002; Lee et al., 2006). In particular, MAP kinase signaling pathways play a fundamental role in the activation of both *Fos* transcription and protein activity (Treisman, 1995; Cahill

et al., 1996b; Murphi et al., 2002; Shaw and Saxton, 2003; Chalmers et al., 2007; O'Donnell et al., 2008). However, pre-existing or newly synthesized Fos protein is not only modified by phosphorylation, but also by ubiquitinylation and sumoylation regulating its transcriptional activity, its sub-cellular localization and its turnover (Papavassiliou et al., 1992; Acquaviva et al., 2002, Murphy et al., 2002, Ferrara et al., 2003, Bossis et al., 2003, 2005; Sasaki et al., 2006; Basbous et al., 2007, 2008). In addition, Fos activity is modulated by physical interactions with other transcription factors, co-factors, and other nuclear proteins (Wagner, 2001; Kassel et al., 2004; Ivorra et al., 2006; Gonzalez et al., 2008).

Fos function in normal development and pathophysiological condition

Many important insights regarding the specific function of Fos protein in development and disease have been obtained from genetically modified mice (Tables 1 and 2) and cells derived thereof (Hess et al., 2001;

Wagner, 2001). Mutant mice with homozygous *Fos* deletion (*Fos*^{-/-}) exhibited a significant loss of viability at birth and only 40% survive and grow at normal rate until they develop severe osteopetrosis. Among other abnormalities these mice showed altered haematopoiesis and behavior (Johnson et al., 1992, Wang et al., 1992).

Immune system development and function

In *Fos*-deficient mice, B cell numbers were reduced in the spleen, lymph nodes and the peripheral blood as a result of a marked reduction in the number of clonogenic B cell precursors. However, *in vitro* differentiation and bone marrow reconstitution experiments demonstrated that haematopoietic stem cells lacking Fos have full developmental potential and that the observed defect in B cell development is most likely due to the impaired bone marrow environment as a consequence of osteopetrosis (Okada et al., 1994).

Fos is also rapidly induced in stimulated T cells and contributes to T cell homeostasis and activation by the

Table 1. Overview on mouse strains with *Fos*-deletions.

Mouse strain	Affected cell type / tissue	Phenotype
<i>Fos</i> ^{-/-}	Osteoclast / osteoblast / bone Mast cell / immune system T cell / immune system Neuron / CNS	Osteopetrosis Impaired osteoblast proliferation Degranulation defect Impaired <i>Tcrb</i> recombination Abnormal behavior Impaired light-induced photoreceptor cell death Increased kainic-acid-induced cell death
<i>Fos</i> ^{ΔCNS}	Keratinocyte / skin Neuron / CNS	Impaired skin carcinogenesis Impaired spatial and associative learning
<i>Fos</i> ^{Δep}	Keratinocyte / skin	Impaired skin carcinogenesis
<i>Fos</i> ^{Fosl1/Fosl1}	Osteoclast / bone Neuron / CNS	Rescue of osteopetrosis Rescue of light-induced photoreceptor cell death

The first column shows the specific mouse strains with complete or tissue specific *Fos*-deletions. The affected cell types and/or tissues are listed in the second column, and the third column summarizes the specific phenotypes, which have been described for the respective mouse strain. CNS: central nervous system, ep: epidermis, *Fosl1*: FOS-like antigen 1.

Table 2. Overview on *Fos*-transgenic mouse strains.

Mouse strain	Affected cell type / tissue	Phenotype
<i>MT-Fos-LTR</i>	Chondroblast / osteoblast / bone	Osteosarcoma
<i>H2-Fos-LTR</i>	Chondroblast / osteoblast / bone	Osteosarcoma
<i>H2-Fos-LTR / H2-Jun-LTR</i>	Chondroblast / osteoblast / bone	Accelerated osteosarcoma formation
<i>H2-Fos-LTR / JunAA</i>	Chondroblast / osteoblast / bone	Reduced osteosarcoma
<i>H2-Fos-LTR / Rsk2^{ly}</i>	Chondroblast / osteoblast / bone	Reduced osteosarcoma
<i>hK1-vFos</i>	Keratinocyte / skin	Epidermal hyperplasia and squamous papillomas
<i>bK5/A-Fos</i>	Keratinocyte / skin	Reduced squamous tumors during chemically induced skin carcinogenesis

The first column shows the genotype of specific mouse strains. The affected cell types and/or tissues are listed in the second column, and the third column summarizes the specific transgene-induced phenotypes. MT: inducible metallothionein promoter, H2: MHC class I H2-K^b promoter, LTR: polyadenylation signal from the FBJ virus, hK1: human keratin-1 promoter, bK5: bovine keratin-5 promoter.

regulation of various cytokines (Macian et al., 2000, 2001; Martins et al., 2008). However, upon T cell receptor stimulation *Fos*-deficient mice were comparable to wild-type controls with regard to peripheral T cells proliferate and cytokine production (Jain et al., 1994). Moreover, Fos is not essential for the regulation of T cell apoptosis that plays an important role in T cell development, positive and negative selection, and function (Gajate et al., 1996; Bierbaum et al., 2003). These data suggested that other Fos family members could substitute for Fos function during T cell homeostasis and activation. However, *Fos*^{-/-} mice showed a considerable inhibition of early T cell development with significant lower thymocyte numbers compared to wild-type controls (Wang et al., 1992, 2008). This phenotype is, at least in part, due to an unexpected function of *Fos* as a direct regulator of T cell antigen receptor- β (*Tcrb*) recombination by binding to an AP-1-binding site in a recombination signal sequence and physical interaction with RAG recombinases (Wang et al., 2008). It is noteworthy that the regulation of *Tcrb* recombination by Fos is independent of its usual function as a transcriptional regulator.

Fos expression is potently induced by aggregation of the surface Fc ϵ RI receptor on mast cells, suggesting a functional implication in mast cell activation and/or function (Baranes and Razin, 1991). Mast cells are tissue-localized effector cells of the innate immune response implicated in inflammatory processes and initiation of adaptive immune responses by recruiting T cells to draining lymph nodes of an infected site. Indeed, *Fos*-deficient mast cells showed a severe Fc ϵ RI-mediated degranulation defect, accompanied by altered expression of various cytokines and proteins, such as Swap70, Vamp7, and Syt1, directly involved in the degranulation process (Lee et al., 2004).

Bone development and remodeling

Bone is a dynamic organ that is characterized by continuous tissue renewal and the integrity of bone function is assured by a tightly controlled balance between bone formation and resorption facilitated by tightly adjusted action of osteoblasts and osteoclasts, respectively (Karsenty, 2003). The expression pattern of Fos protein during mouse embryogenesis and in adult tissues indicated a possible role in bone development




Fig. 1. The functional integration of Fos/AP-1 signaling. Numerous extra- and intracellular stimuli induce transcription and/or activity of Fos/AP-1. Upon activation Fos/AP-1 regulates the expression of downstream target genes implicated in the regulation of various cellular processes, and thereby contributes to normal physiological as well as pathological conditions, including cancer.

and remodeling. Indeed, ectopically expressed *Fos* protein in transgenic mice specifically affected the skeleton, and *Fos* knock-out mice exhibited severe osteopetrosis due to a complete lack of mature osteoclasts (Ruther et al., 1987; Johnson et al., 1992; Wang et al., 1992; Grigoriadis et al., 1994). The signal transduction pathways operating in osteoclastogenesis have been extensively studied and it turned out that Fos is at the receiving end of several signaling cascades triggered by essential growth factors such as Csf1 and Tnfsf11 (also known as M-CSF and RANKL) (Wagner and Matsuo, 2003; Wagner and Eferl, 2005). Tnfsf11 is a member of the TNF superfamily and was initially identified on activated T cells. However, it was shown subsequently that Tnfsf11 is also expressed on the surface of osteoblasts and is a key molecule in the induction of osteoclastogenesis (Takahashi et al., 1999; Wagner and Eferl, 2005). Under pathogenic conditions such as rheumatoid arthritis (RA), Tnfsf11 is secreted by a variety of synovial cells, including activated T cells, thereby promoting extensive osteoclastogenesis and bone resorption (Zenz et al., 2008). RA is considered an autoimmune disorder and is characterized by synovial inflammation, joint destruction, and excessive subchondrial bone resorption. In addition to osteoclast-mediated bone erosion the generation of pro-inflammatory cytokines and matrix metalloproteinases (MMPs) is important in the pathogenesis of RA. Thus,

therapies targeting respective cytokines are highly effective but still insufficient for sustained clinical remission (Scott and Kingsley, 2006). Both pro-inflammatory cytokines and MMPs are well-known targets of Fos/AP-1, and ectopic over-expression of Fos in transgenic mice leads to MMP induction and joint destruction (Shiozawa et al., 1992; Gack et al., 1994), supporting the hypothesis that Fos is an important contributor to inflammatory bone disease and can affect the severity of RA. The essential requirement of osteoclasts and Fos expression in RA was demonstrated in transgenic mice expressing human TNF α (*hTNFtg* mice) that develop several hallmarks of RA. The breeding of *hTNFtg* mice into a *Fos*-deficient background resulted in a complete absence of osteoclasts and an efficient protection from bone erosion (Redlich et al., 2002). Moreover, administration of short double-stranded DNA oligonucleotides sharing an AP-1-binding motif or a selective small molecule inhibitor of Fos/AP-1 reduced the amount of inflammatory cytokines, as well as MMPs, and inhibited or resolved arthritis in a preclinical mouse model of the disease (Shiozawa et al., 1997; Aikawa et al., 2008).

Fos11, which encodes the Fos family member Fra1, and the nuclear factor of activated T cells c1 (*Nfatc1*) have been identified as direct Fos target genes in osteoclasts (Takayanagi et al., 2002). Accordingly, *Fos*-dependent functions in osteoclasts can be substituted by




Fig. 2. Fos/AP-1 regulated processes and target genes in cancer. Fos/AP-1 is a central regulator of tumor-associated target genes during carcinogenesis and is critically involved in cellular processes, such as proliferation, apoptosis, angiogenesis, epidermal-mesenchymal-transition (EMT), invasion and metastasis.

ectopic NFAT or Fra1 expression, or in the case of replacement of the *Fos* gene locus by the *Fosl1* gene (*Fos^{Fosl1/Fosl1}*) (Fleischmann et al., 2000; Matsuo et al., 2000, 2004). Another *Fos* target gene, *Ifnb1*, is an antagonist of osteoclastogenesis interfering with Tnfsf11-induced expression of Fos protein in osteoclast precursors, supporting the existence of a negative feedback loop that prevents extensive osteoclastogenic activity of Fos (Takayanagi et al., 2002).

Although Fos seems to be dispensable in determining the osteoblastic lineage *in vivo*, *Fos*-deficient osteoblasts exhibited impaired growth behavior in culture, indicating that Fos is implicated in the control of osteoblast proliferation (Fu et al., 2005). The same study also unraveled an attractive model in which the hormone leptin determines the extent of bone formation by a new molecular mechanism involving sympathetic signaling, Fos/AP-1 activity, and molecular clock gene regulation.

Fos function in the central nervous system

The unique morphological and excitable properties of nerve cells endow them with specialized properties that permit the reception, transmission, and storage of information. It is well-established that trans-synaptic signals cause rapid responses in neurons occurring over a time frame ranging from milliseconds (e.g. opening of ligand-gated channels) to seconds and minutes (e.g. second messenger-mediated events). Meanwhile, we know that trans-synaptic activation also elicits slower, long-term responses in neuronal cells that are correlated with - and in most cases depend on - induction of new genetic programs.

Despite the fact that *Fos* transcription is markedly induced in neuronal cells by neurotransmitters, electric excitation and growth factors *in vitro*, and during stimulation of the intact nervous system *in vivo* (Sagar et al., 1988; Sheng and Greenberg, 1990), *Fos*-deficient mice did not exhibit an obvious defect in central nervous system (CNS) development. However, emerging evidence suggests that Fos is essential in regulating neuronal cell survival versus cell death. As an example, ablation of Fos prevented light-induced photoreceptor cell death and retinal degeneration, suggesting a pro-apoptotic function of Fos in this cell type (Hafezi et al., 1997). Similar to the situation in osteoclasts, a *Fosl1* knock-in into the *Fos* gene locus could substitute for Fos functions during light-induced apoptosis of photoreceptor cells (Fleischmann et al., 2000). Recently, two different pathways of light-induced photoreceptor cell death, depending either on transducin or AP-1 activity, were suggested, and specific genetic programs as well as gene regulatory networks were predicted, employing global gene expression analysis on samples from several knock-out mouse models (Hao et al., 2002; Krishnan et al., 2008). Yet, in contrast to the situation in photoreceptor cells, Fos turned out to be a crucial genetic regulator of neuronal excitability and survival in

a mouse model of kainic-acid-induced seizures (Zhang et al., 2002b).

In addition to its role in neuronal cell survival versus cell death, Fos has been postulated to participate in the molecular mechanisms of learning and memory (Paylor et al., 1994; Tischmeyer and Grimm, 1999). Despite a strong induction of Fos expression in the hippocampus after spatial learning, mutant mice carrying a hippocampal region-specific Fos deletion, exhibited normal spatial learning behaviors in both Morris water maze and Barnes maze tests (Zhang et al., 2002). In contrast, Fleischmann and colleagues demonstrated in a mouse model with a CNS-specific Fos deletion (*Fos^{ΔCNS}*) that mutant animals exhibited normal general and emotional behavior but were specifically impaired in hippocampus-dependent spatial and associative learning tasks (Fleischmann et al., 2003). These learning deficits were most likely due to a reduction of NMDA receptor-dependent long-term potentiation in hippocampal synapses. In a more recent study, antisense oligonucleotide microinfusion or *Fos*-deficient mice were used to demonstrate that *Fos*-mediated gene transcription in the parabrachial nucleus, amygdala, or insular cortex plays a crucial role in the acquisition and/or consolidation, but not the retrieval, of long-term taste memory (Yasoshima et al., 2006).

As immunohistochemical staining or *in situ* hybridization of brain sections have revealed a significant anatomical and temporal specificity of Fos expression in the CNS, particularly under stress conditions, Fos became the most widely used biomarker and extremely powerful tool to monitor neuronal activity *in vivo* or *ex vivo* and to reveal the connection between activated neurons within the CNS (Sheng and Greenberg, 1990; Kovacs, 2008). Meanwhile, several transgenic animal models have been established that utilize the *Fos* promoter for simple, rapid, and quantitative activity mapping in the CNS *in vivo* or to drive expression of genes of interest in activated neurons (Smeyne et al., 1992; Robertson et al., 1995; Muphy et al., 2004; Reijmers et al., 2007; Matsuo et al., 2008).

Fos function in cancer development and progression

In the past, many studies focused on the oncogenic function of Fos protein and highlighted its key role in neoplastic transformation and epithelial-to-mesenchymal transition leading to invasive growth of cancer cells and metastasis. Initially, Fos was identified as an oncoprotein in the Finkel Biskis-Jinkis osteosarcoma virus and the fact that its function was augmented by growth factors, membrane-bound and cytoplasmatic oncogenes, as well as carcinogens and tumor-promoting agents supported the idea that Fos is a potent oncogenic transcription factor (Curran et al., 1983; Van Beveren et al., 1983; Angel and Karin, 1991). In this regard, several reports demonstrated *Fos* amplification or expression in human tumor tissues, such as osteosarcomas (Gamberi et al., 1998; Papachristou et al., 2003), cervical cancer (Prusty

and Das, 2005), endometrial carcinomas (Bamberger et al., 2001), hepatocellular carcinomas (Yuen et al., 2001), ovarian cancer (Tsuda et al., 2004), and in some human cancers Fos protein levels correlated with malignant progression or poor prognosis (Volm et al., 1993; Aoyagi et al., 1998; Mahner et al., 2008).

Again, several genetically modified mice exhibiting alterations predominantly in bone and skin have shed light on the role of Fos in the context of tumor formation and malignant progression *in vivo* (Tables 1 and 2).

Bone tumors

When widely over-expressed in transgenic mice (*MT-Fos-LTR* or *H2-Fos-LTR*), ectopic Fos expression caused osteosarcoma formation by transformation of chondroblasts and osteoblasts, which identifies these two cell types as specific cellular targets of Fos-induced tumorigenesis (Ruther et al., 1989; Wang et al., 1991; Grigoriadis et al., 1993). Activation of Fos in transgenic mice and osteoblast cell lines resulted in strong up-regulation of cell cycle regulators (e.g. Cyclin D1, Cyclin A and Cyclin E), which may contribute to uncontrolled proliferation (Sunters et al., 1998, 2004). *Fos-Jun* double transgenic mice developed osteosarcomas at a higher frequency than single *Fos* transgenic animals, suggesting a cooperative effect (Wang et al., 1995). Indeed, crossing *H2-Fos-LTR* mice with animals harboring mutant *Jun* alleles that had the Jun N-terminal kinase (Jnk) phospho-acceptor serines changed to alanine (*JunAA*) revealed reduced formation of bone lesions (Behrens et al., 2000). These data confirm that the phosphorylated Jun protein is an important partner for oncogenic Fos and that the Jun/Fos heterodimeric complex regulates proliferation and cellular transformation of osteoblasts *in vivo*. It is worth noting that impaired osteosarcoma formation in *H2-Fos-LTR* mice was also observed in the absence of the growth factor-regulated S6 kinase (Rsk2), supporting that Fos-dependent transformation of bone cells requires post-translational regulation via Rsk2 signaling (David et al., 2005). Indeed, lack of Fos phosphorylation at Ser362 by Rsk2 resulted in rapid protein destabilization and has been thought to be responsible for decreased proliferation and increased apoptosis of transformed osteoblasts.

Skin tumors

Greenhalgh and colleagues generated transgenic mice that express v-Fos under the control of the human *keratin-1* promoter (*hK1-vFos*) to investigate the role of activated Fos protein in the transformation of keratinocytes *in vivo* (Greenhalgh et al., 1993b). Adult transgenic mice displayed hyperplasia and hyperkeratosis and developed benign squamous papillomas after long latency. Meanwhile, they crossed *hK1-vFos* transgenic animals with numerous genetically modified mouse strains to unravel the synergism of v-

Fos with other oncogenes and/or tumor suppressor genes, such as *Ras*, *Tgfa*, *Tp53*, and *Pten*, in neoplastic transformation of epidermal keratinocytes (Greenhalgh et al., 1993; Wang et al., 1995, 2000; Yao et al., 2008). The role of Fos-containing protein complexes during multistage skin carcinogenesis was further investigated using another transgenic mouse model in which a negative Fos mutant was conditionally expressed in keratinocytes (*bK5/A-Fos*). Whereas inhibition of Fos/AP-1 activity during chemically induced skin carcinogenesis dramatically reduced the number of benign and malignant squamous lesions, expression of A-Fos after tumor formation caused squamous tumors to trans-differentiate into sebaceous adenomas (Gerdes et al., 2006). Thus Fos/AP-1 activity in keratinocytes regulates tumor cell lineages and is essential to maintain the squamous tumor cell identity. In line with these data, *Fos^{-/-}* mice, mice expressing a transactivation negative version of the Fos partner Jun and animals that specifically lack Fos expression in keratinocytes (*Fos^{Δep}*) showed reduced tumor formation in mouse models of skin carcinogenesis and revealed an essential function of Fos during late stages of tumor development (Saez et al., 1995; Young et al., 1999; Durchdewald et al., 2008).

Yet, how could Fos affect malignant progression of epithelial tumor cells? One possible answer was found by Reichmann and colleagues, who showed that over-expression of a conditional FosER fusion protein in mammary epithelial cells caused a loss of epithelial polarity and augmented invasive growth, most likely by induced epithelial-mesenchymal transition (EMT) (Reichmann et al., 1992). EMT is a critical process in tumor progression and metastasis providing tumor cells with the capability to escape from the primary tumor, to invade the surrounding tissues, and to migrate to distant regions of the body. Characteristic molecular features of EMT are loss of cell-cell adhesion and apical-basal cell polarity, as well as the increased motility of cells accompanied by nuclear translocation of β -catenin, accelerated TGF- β signaling, loss of epithelial markers, such as E-cadherin, and gain of mesenchymal markers, such as vimentin (Thiery and Sleeman, 2006; Jeanes et al., 2008). Indeed, all these features could be detected in epithelial cells with ectopic Fos over-expression (Eger et al., 2000, 2004; Mejlvang et al., 2007).

Fos target genes in cancer

The identification of key regulators of distinct molecular processes in cancer cells that are under the direct control of Fos is essential to understand its function during tumor development and to find additional therapeutic targets for novel strategies of translational cancer research. Despite the well-documented function of Fos in neoplastic transformation and malignant progression, only a few unambiguously identified tumor-associated target genes have been described so far. Therefore, genome-wide approaches in

informative tumour models are necessary in order to define Fos-dependent genetic programs in cancer that will most likely vary according to the tumor type and the conditions. In the past, Ozanne and colleagues performed gene expression analysis comparing control fibroblasts with v-Fos transformed fibroblasts and found many candidate genes implicated in cellular processes of cytoskeleton rearrangement, motility, and proteolysis, suggesting that Fos target genes are important effectors of cellular invasion (Scott et al., 2004; Ozanne et al., 2007). In line with this assumption, Fos-dependent gene transcription has been shown to drive invasive tumor growth in *Drosophila* (Uhlirova and Bohmann, 2006).

More recently, we analyzed skin tumor samples from control and *Fos^{Δep}* mice that developed due to ectopic expression of a constitutive active mutant of human son of sevenless (SOS-F), a potent upstream activator of oncogenic Ras, in keratinocytes (Sibilia et al., 2000). Genome-wide gene expression analysis revealed a comprehensive list of 372 differentially expressed genes that significantly discriminate skin tumors from *SOS-F/Fos^{flxed}* and *SOS-F/Fos^{Δep}* animals (Durchdewald et al., 2008). Numerous genes of this list were previously identified as tumor-associated candidates in mouse models of skin carcinogenesis, and gene clustering according to their functional annotation showed that most of them are implicated in distinct tumorigenic features, such as cellular movement and morphology, cell cycle control, cell death and cell signaling (Hummerich et al., 2006; Durchdewald et al., 2008). Interestingly, one candidate gene whose expression critically depends on Fos activity encoded the small mucin-like glycoprotein podoplanin (Pdpn). Pdpn has attracted great interest in the field of cancer research since its expression correlated with malignant progression and metastasis, and could promote tumor cell invasion *in vitro* and *in vivo* by EMT-dependent and -independent mechanisms (Wicki et al., 2006; Wicki and Christofori, 2007).

Conclusion and Outlook

In conclusion, a large body of experimental evidence clearly demonstrates a unique role of the transcription factor Fos in normal tissue development and homeostasis, and that deregulation of Fos activity critically contributes to pathophysiological processes, including cancer. However, genome-wide approaches and detailed analysis of Fos-dependent genetic programs will be essential to comprehensively understand the causal connectivity between altered Fos activity and distinct human disorders.

There is a controversial discussion on the question whether transcription factors themselves, such as Fos, could serve as suitable drug targets for clinical application. Some general doubts are that (i) Fos is ubiquitously expressed and critical for numerous important cellular processes, (ii) Fos is a member of a larger protein family showing putative redundant

functions under pathophysiological conditions and/or in transformed cells, and (iii) frequent mutations in the *Fos* coding region have not been identified so far that could serve as putative target site for drug interference. However, using three-dimensional pharmacophore modeling Aikawa and colleagues succeeded in *de novo* design of a specific small-molecule inhibitor for Fos/AP-1 that resolved arthritis in a preclinical mouse model (Aikawa et al., 2008). Although additional clinical studies are required to determine its therapeutic efficacy, this inhibitor might also be suitable for other clinical applications, including cancer therapy. Yet, in contrast to the classical concept of Fos as an oncogenic transcription factor, a more recent study in *Trp53/Fos* double knockout mice that developed highly proliferative and invasive rhabdomyosarcomas has raised the idea that it also has tumor-suppressive functions in specific cancer cells, and caution against the therapeutic use of Fos inhibitors in some human cancers (Eferl and Wagner, 2003; Fleischmann et al., 2003). Furthermore, Fos expression levels in tissue samples of human non-small cell lung cancer and thyroid carcinoma were significantly lower compared to normal tissue (Levin et al., 1995; Liu et al., 1999), and loss of Fos expression in human gastric and ovarian carcinomas correlated with disease progression and was independently associated with unfavorable progression-free as well as overall survival (Welsh et al., 2001; Meinhold-Heerlein et al., 2005; Jin et al., 2007; Mahner et al., 2008).

Despite the fact that Fos was identified more than two decades ago, it still maintains a lot of its mystery. However, the availability of a large variety of defined mouse models and indicative downstream target genes is a promising starting point for novel drug development and drug assessment in the near future.

Acknowledgements. We gratefully acknowledge Gustavo Acuna and Marina Schorpp-Kistner for helpful discussion and reading of the manuscript. This work was supported by the German Ministry for Education and Research (National Genome Research Network NGFN-2, 01GS0460 to P.A.), the *Deutsche Krebshilfe* e.V. (to P.A. and J.H.) and the SBCancer Program of the Helmholtz Society (to P.A. and J.H.). M.D. was supported by the *Studienstiftung des deutschen Volkes*.

References

- Acquaviva C., Bossis G., Ferrara P., Brockly F., Jariel-Encontre I. and Piechaczyk M. (2002). Multiple degradation pathways for Fos family proteins. *Ann. NY Acad. Sci.* 973, 426-434.
- Aikawa Y., Morimoto K., Yamamoto T., Chaki H., Hashiramoto A., Narita H., Hirano S. and Shiozawa S. (2008). Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. *Nat. Biotechnol.* 26, 817-823.
- Angel P. and Karin M. (1991). The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim. Biophys. Acta* 1072, 129-157.
- Aoyagi K., Shima I., Wang M., Hu Y., Garcia F.U. and Stearns M.E.

- (1998). Specific transcription factors prognostic for prostate cancer progression. *Clin. Cancer Res.* 4, 2153-2160.
- Bamberger A.M., Milde-Langosch K., Rossing E., Goemann C. and Loning T. (2001). Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. *J. Cancer. Res. Clin. Oncol.* 127, 545-550.
- Baranes D. and Razin E. (1991). Protein kinase C regulates proliferation of mast cells and the expression of the mRNAs of fos and jun proto-oncogenes during activation by IgE-Ag or calcium ionophore A23187. *Blood* 78, 2354-2364.
- Basbous J., Chalbos D., Hipskind R., Jariel-Encontre I. and Piechaczyk M. (2007). Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. *Mol. Cell Biol.* 27, 3936-3950.
- Basbous J., Jariel-Encontre I., Gomard T., Bossis G. and Piechaczyk M. (2008). Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer? *Biochimie* 90, 296-305.
- Behrens A., Jochum W., Sibilia M. and Wagner E.F. (2000). Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. *Oncogene* 19, 2657-2663.
- Bierbaum H., Baumann S., Herr I., Tuckermann J.P., Hess J., Schorpp-Kistner M. and Angel P. (2003). Early activation and induction of apoptosis in T cells is independent of c-Fos. *Ann. NY Acad. Sci.* 1010, 225-231.
- Bossis G., Ferrara P., Acquaviva C., Jariel-Encontre I. and Piechaczyk M. (2003). c-Fos proto-oncoprotein is degraded by the proteasome independently of its own ubiquitinylation in vivo. *Mol. Cell Biol.* 23, 7425-7436.
- Bossis G., Malnou C.E., Farras R., Andermarcher E., Hipskind R., Rodriguez M., Schmidt D., Muller S., Jariel-Encontre I. and Piechaczyk M. (2005). Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. *Mol. Cell Biol.* 25, 6964-6979.
- Cahill M.A., Janknecht R. and Nordheim A. (1996). Signalling pathways: jack of all cascades. *Curr. Biol.* 6, 16-19.
- Chalmers C.J., Gilley R., March H.N., Balmanno K. and Cook S.J. (2007). The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1. *Cell Signal.* 19, 695-704.
- Curran T., MacConnell W.P., van Straaten F. and Verma I.M. (1983). Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. *Mol. Cell Biol.* 3, 914-921.
- David J.P., Mehic D., Bakiri L., Schilling A.F., Mandic V., Priemel M., Idarraga M.H., Reschke M.O., Hoffmann O., Amling M. and Wagner E.F. (2005). Essential role of RSK2 in c-Fos-dependent osteosarcoma development. *J. Clin. Invest.* 115, 664-672.
- Durchdewald M., Guinea-Viniegra J., Haag D., Riehl A., Lichter P., Hahn M., Wagner E.F., Angel P. and Hess J. (2008). Podoplanin is a novel fos target gene in skin carcinogenesis. *Cancer Res.* 68, 6877-6883.
- Eferl R. and Wagner E.F. (2003). AP-1: a double-edged sword in tumorigenesis. *Nat. Rev. Cancer* 3, 859-868.
- Eger A., Stockinger A., Park J., Langkopf E., Mikula M., Gotzmann J., Mikulits W., Beug H. and Foisner R. (2004). beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. *Oncogene* 23, 2672-2680.
- Eger A., Stockinger A., Schaffhauser B., Beug H. and Foisner R. (2000). Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. *J. Cell Biol.* 148, 173-188.
- Ferrara P., Andermarcher E., Bossis G., Acquaviva C., Brockly F., Jariel-Encontre I. and Piechaczyk M. (2003). The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. *Oncogene* 22, 1461-1474.
- Fleischmann A., Hafezi F., Elliott C., Reme C.E., Ruther U. and Wagner E.F. (2000). Fra-1 replaces c-Fos-dependent functions in mice. *Genes Dev.* 14, 2695-2700.
- Fleischmann A., Hvalby O., Jensen V., Strelakova T., Zacher C., Layer L.E., Kvello A., Reschke M., Spanagel R., Sprengel R., Wagner E.F. and Gass P. (2003). Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. *J. Neurosci.* 23, 9116-9122.
- Fleischmann A., Jochum W., Eferl R., Witowsky J. and Wagner E.F. (2003). Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. *Cancer Cell* 4, 477-482.
- Franchi A., Calzolari A. and Zampi G. (1998). Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. *Virchows Arch.* 432, 515-519.
- Fu L., Patel M.S., Bradley A., Wagner E.F. and Karsenty G. (2005). The molecular clock mediates leptin-regulated bone formation. *Cell* 122, 803-815.
- Gack S., Vallon R., Schaper J., Ruther U. and Angel P. (1994). Phenotypic alterations in fos-transgenic mice correlate with changes in Fos/Jun-dependent collagenase type I expression. Regulation of mouse metalloproteinases by carcinogens, tumor promoters, cAMP, and Fos oncoprotein. *J. Biol. Chem.* 269, 10363-10369.
- Gajate C., Alonso M.T., Schimmang T. and Mollinedo F. (1996). C-Fos is not essential for apoptosis. *Biochem. Biophys. Res. Commun.* 218, 267-272.
- Gamberi G., Benassi M.S., Bohling T., Ragazzini P., Molendini L., Sollazzo M.R., Pompetti F., Merli M., Magagnoli G., Balladelli A. and Picci P. (1998). C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. *Oncology* 55, 556-563.
- Gerdes M.J., Myakishev M., Frost N.A., Rishi V., Moitra J., Acharya A., Levy M.R., Park S.W., Glick A., Yuspa S.H. and Vinson C. (2006). Activator protein-1 activity regulates epithelial tumor cell identity. *Cancer Res.* 66, 7578-7588.
- Gonzalez J.M., Navarro-Puche A., Casar B., Crespo P. and Andres V. (2008). Fast regulation of AP-1 activity through interaction of lamin A/C, ERK1/2, and c-Fos at the nuclear envelope. *J. Cell Biol.* 183, 653-666.
- Greenhalgh D.A., Quintanilla M.I., Orengo C.C., Barber J.L., Eckhardt J.N., Rothnagel J.A. and Roop D.R. (1993). Cooperation between v-fos and v-rasHA induces autonomous papillomas in transgenic epidermis but not malignant conversion. *Cancer Res.* 53, 5071-5075.
- Greenhalgh D.A., Rothnagel J.A., Wang X.J., Quintanilla M.I., Orengo C.C., Gagne T.A., Bundman D.S., Longley M.A., Fisher C. and Roop D.R. (1993). Hyperplasia, hyperkeratosis and benign tumor production in transgenic mice by a targeted v-fos oncogene suggest a role for fos in epidermal differentiation and neoplasia. *Oncogene* 8, 2145-2157.

Fos in health and disease

- Grigoriadis A.E., Schellander K., Wang Z.Q. and Wagner E.F. (1993). Osteoblasts are target cells for transformation in c-fos transgenic mice. *J. Cell Biol.* 122, 685-701.
- Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A. and Wagner E.F. (1994). c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. *Science* 266, 443-448.
- Hafezi F., Steinbach J.P., Marti A., Munz K., Wang Z.Q., Wagner E.F., Aguzzi A. and Reme C.E. (1997). The absence of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal degeneration in vivo. *Nat. Med.* 3, 346-349.
- Hao W., Wenzel A., Obin M.S., Chen C.K., Brill E., Krasnoperova N.V., Eversole-Cire P., Kleyner Y., Taylor A., Simon M.I., Grimm C., Reme C.E. and Lem J. (2002). Evidence for two apoptotic pathways in light-induced retinal degeneration. *Nat. Genet.* 32, 254-260.
- Hess J., Angel P. and Schorpp-Kistner M. (2004). AP-1 subunits: quarrel and harmony among siblings. *J. Cell Sci.* 117, 5965-5973.
- Hess J., Porte D., Munz C. and Angel P. (2001). AP-1 and Cbfa/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2/AP-1 composite element. *J. Biol. Chem.* 276, 20029-20038.
- Hummerich L., Muller R., Hess J., Kokocinski F., Hahn M., Furstenberger G., Mauch C., Lichter P. and Angel P. (2006). Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. *Oncogene* 25, 111-121.
- Ivorra C., Kubicek M., Gonzalez J.M., Sanz-Gonzalez S.M., Alvarez-Barrientos A., O'Connor J.E., Burke B. and Andres V. (2006). A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. *Genes Dev.* 20, 307-320.
- Jain J., Nalefski E.A., McCaffrey P.G., Johnson R.S., Spiegelman B.M., Papaioannou V. and Rao A. (1994). Normal peripheral T-cell function in c-Fos-deficient mice. *Mol. Cell Biol.* 14, 1566-1574.
- Jeanes A., Gottardi C.J. and Yap A.S. (2008). Cadherins and cancer: how does cadherin dysfunction promote tumor progression? *Oncogene* 27, 6920-6929.
- Jin S.P., Kim J.H., Kim M.A., Yang H.K., Lee H.E., Lee H.S. and Kim W.H. (2007). Prognostic significance of loss of c-fos protein in gastric carcinoma. *Pathol. Oncol. Res.* 13, 284-289.
- Johnson R.S., Spiegelman B.M. and Papaioannou V. (1992). Pleiotropic effects of a null mutation in the c-fos proto-oncogene. *Cell* 71, 577-586.
- Karsenty G. (2003). The complexities of skeletal biology. *Nature* 423, 316-318.
- Kassel O., Schneider S., Heilbock C., Litfin M., Gottlicher M. and Herrlich P. (2004). A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. *Genes Dev.* 18, 2518-2528.
- Kovacs K.J. (2008). Measurement of immediate-early gene activation-c-fos and beyond. *J. Neuroendocrinol.* 20, 665-672.
- Krishnan J., Chen J., Shin K.J., Hwang J.I., Han S.U., Lee G. and Choi S. (2008). Gene expression profiling of light-induced retinal degeneration in phototransduction gene knockout mice. *Exp. Mol. Med.* 40, 495-504.
- Lee H.J., Palkovits M. and Young W.S. 3rd. (2006). miR-7b, a microRNA up-regulated in the hypothalamus after chronic hyperosmolar stimulation, inhibits Fos translation. *Proc. Natl. Acad. Sci. USA* 103, 15669-15674.
- Lee Y.N., Tuckerman J., Nechushtan H., Schutz G., Razin E. and Angel P. (2004). c-Fos as a regulator of degranulation and cytokine production in FcepsilonRI-activated mast cells. *J. Immunol.* 173, 2571-2577.
- Levin W.J., Press M.F., Gaynor R.B., Sukhatme V.P., Boone T.C., Reissmann P.T., Figlin R.A., Holmes E.C., Souza L.M. and Slamon D.J. (1995). Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. *Oncogene* 11, 1261-1269.
- Liu G., Takano T., Matsuzuka F., Higashiyama T., Kuma K. and Amino N. (1999). Screening of specific changes in mRNAs in thyroid tumors by sequence specific differential display: decreased expression of c-fos mRNA in papillary carcinoma. *Endocr. J.* 46, 459-466.
- Macian F., Garcia-Rodriguez C. and Rao A. (2000). Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. *EMBO J.* 19, 4783-4795.
- Macian F., Lopez-Rodriguez C. and Rao A. (2001). Partners in transcription: NFAT and AP-1. *Oncogene* 20, 2476-2489.
- Mahner S., Baasch C., Schwarz J., Hein S., Wolber L., Janicke F. and Milde-Langosch K. (2008). C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. *Br. J. Cancer* 99, 1269-1275.
- Martins G.A., Cimmino L., Liao J., Magnusdottir E. and Calame K. (2008). Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. *J. Exp. Med.* 205, 1959-1965.
- Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., Bachler M.A., Amamo H., Aburatani H., Ishikawa H. and Wagner E.F. (2004). Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. *J. Biol. Chem.* 279, 26475-26480.
- Matsuo K., Owens J.M., Tonko M., Elliott C., Chambers T.J. and Wagner E.F. (2000). Fos1 is a transcriptional target of c-Fos during osteoclast differentiation. *Nat. Genet.* 24, 184-187.
- Matsuo N., Reijmers L. and Mayford M. (2008). Spine-type-specific recruitment of newly synthesized AMPA receptors with learning. *Science* 319, 1104-1107.
- Meinhold-Heerlein I., Bauerschlag D., Hilpert F., Dimitrov P., Sapinoso L.M., Orłowska-Volk M., Bauknecht T., Park T.W., Jonat W., Jacobsen A., Sehouli J., Luttgies J., Krajewski M., Krajewski S., Reed J.C., Arnold N. and Hampton G.M. (2005). Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. *Oncogene* 24, 1053-1065.
- Mejlvang J., Kriajevska M., Berditchevski F., Bronstein I., Lukanidin E.M., Pringle J.H., Mellon J.K. and Tulchinsky E.M. (2007). Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition. *Exp. Cell Res.* 313, 380-393.
- Murphy L.O., Smith S., Chen R.H., Fingar D.C. and Blenis J. (2002). Molecular interpretation of ERK signal duration by immediate early gene products. *Nat. Cell Biol.* 4, 556-564.
- Murphy M., Greferath U., Nag N., Nithianantharajah J. and Wilson Y.M. (2004). Tracing functional circuits using c-Fos regulated expression of marker genes targeted to neuronal projections. *Front. Biosci.* 9, 40-47.
- O'Donnell A., Yang S.H. and Sharrocks A.D. (2008). MAP kinase-mediated c-fos regulation relies on a histone acetylation relay

- switch. *Mol. Cell* 29, 780-785.
- Okada S., Wang Z.Q., Grigoriadis A.E., Wagner E.F. and von Ruden T. (1994). Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment. *Mol. Cell Biol.* 14, 382-390.
- Ozanne B.W., Spence H.J., McGarry L.C. and Hennigan R.F. (2007). Transcription factors control invasion: AP-1 the first among equals. *Oncogene* 26, 1-10.
- Papachristou D.J., Batistatou A., Sykiotis G.P., Varakis I. and Papavassiliou A.G. (2003). Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. *Bone* 32, 364-371.
- Papavassiliou A.G., Treier M., Chavrier C. and Bohmann D. (1992). Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun. *Science* 258, 1941-1944.
- Paylor R., Johnson R.S., Papaioannou V., Spiegelman B.M. and Wehner J.M. (1994). Behavioral assessment of c-fos mutant mice. *Brain. Res.* 651, 275-282.
- Prusty B.K. and Das B.C. (2005). Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. *Int. J. Cancer* 113, 951-960.
- Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J.S., Wagner E.F. and Schett G. (2002). Osteoclasts are essential for TNF-alpha-mediated joint destruction. *J. Clin. Invest.* 110, 1419-1427.
- Reichmann E., Schwarz H., Deiner E.M., Leitner I., Eilers M., Berger J., Busslinger M. and Beug H. (1992). Activation of an inducible c-FosER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid cell conversion. *Cell* 71, 1103-1116.
- Reijmers L.G., Perkins B.L., Matsuo N. and Mayford M. (2007). Localization of a stable neural correlate of associative memory. *Science* 317, 1230-1233.
- Robertson L.M., Kerppola T.K., Vendrell M., Luk D., Smeyne R.J., Bocchiaro C., Morgan J.I. and Curran T. (1995). Regulation of c-fos expression in transgenic mice requires multiple interdependent transcription control elements. *Neuron* 14, 241-252.
- Ruther U., Garber C., Komitowski D., Muller R. and Wagner E.F. (1987). Deregulated c-fos expression interferes with normal bone development in transgenic mice. *Nature* 325, 412-416.
- Ruther U., Komitowski D., Schubert F.R. and Wagner E.F. (1989). c-fos expression induces bone tumors in transgenic mice. *Oncogene* 4, 861-865.
- Saez E., Rutberg S.E., Mueller E., Oppenheim H., Smoluk J., Yuspa S. H. and Spiegelman B.M. (1995). c-fos is required for malignant progression of skin tumors. *Cell* 82, 721-732.
- Sagar S.M., Sharp F.R. and Curran T. (1988). Expression of c-fos protein in brain: metabolic mapping at the cellular level. *Science* 240, 1328-1331.
- Sasaki T., Kojima H., Kishimoto R., Ikeda A., Kunimoto H. and Nakajima K. (2006). Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role. *Mol. Cell* 24, 63-75.
- Scott D.L. and Kingsley G.H. (2006). Tumor necrosis factor inhibitors for rheumatoid arthritis. *N. Engl. J. Med.* 355, 704-712.
- Scott L.A., Vass J.K., Parkinson E.K., Gillespie D.A., Winnie J.N. and Ozanne B.W. (2004). Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation, immortalization, and the tumor suppressors p16INK4a and p53. *Mol. Cell Biol.* 24, 1540-1559.
- Shaulian E. and Karin M. (2002). AP-1 as a regulator of cell life and death. *Nat. Cell Biol.* 4, E131-136.
- Shaw P.E. and Saxton J. (2003). Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. *Int. J. Biochem. Cell Biol.* 35, 1210-1226.
- Sheng M. and Greenberg M.E. (1990). The regulation and function of c-fos and other immediate early genes in the nervous system. *Neuron* 4, 477-485.
- Shiozawa S., Shimizu K., Tanaka K. and Hino K. (1997). Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. *J. Clin. Invest.* 99, 1210-1216.
- Shiozawa S., Tanaka Y., Fujita T. and Tokuhisa T. (1992). Destructive arthritis without lymphocyte infiltration in H2-c-fos transgenic mice. *J. Immunol.* 148, 3100-3104.
- Sibilia M., Fleischmann A., Behrens A., Stingl L., Carroll J., Watt F.M., Schlessinger J. and Wagner E.F. (2000). The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. *Cell* 102, 211-220.
- Smeyne R.J., Schilling K., Robertson L., Luk D., Oberdick J., Curran T. and Morgan J.I. (1992). fos-lacZ transgenic mice: mapping sites of gene induction in the central nervous system. *Neuron* 8, 13-23.
- Sunters A., McCluskey J. and Grigoriadis A.E. (1998). Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation. *Dev. Genet.* 22, 386-397.
- Sunters A., Thomas D.P., Yeudall W.A. and Grigoriadis A.E. (2004). Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity. *J. Biol. Chem.* 279, 9882-9891.
- Takahashi N., Udagawa N. and Suda T. (1999). A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANSC/RANKL, regulates osteoclast differentiation and function. *Biochem. Biophys. Res. Commun.* 256, 449-455.
- Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E.F., Mak T.W., Kodama T. and Taniguchi T. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. *Dev. Cell* 3, 889-901.
- Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., Yokochi T., Oda H., Nakamura K., Ida N., Wagner E.F. and Taniguchi T. (2002). RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. *Nature* 416, 744-749.
- Thiery J.P. and Sleeman J.P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. *Nat. Rev. Mol. Cell Biol.* 7, 131-142.
- Tischmeyer W. and Grimm R. (1999). Activation of immediate early genes and memory formation. *Cell Mol. Life Sci.* 55, 564-574.
- Treisman R. (1995). Journey to the surface of the cell: Fos regulation and the SRE. *EMBO J.* 14, 4905-4913.
- Tsuda H., Birrer M.J., Ito Y.M., Ohashi Y., Lin M., Lee C., Wong W.H., Rao P.H., Lau C.C., Berkowitz R.S., Wong K.K. and Mok S.C. (2004). Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. *Cancer Genet. Cytogenet.* 155, 97-107.
- Uhlirva M. and Bohmann D. (2006). JNK- and Fos-regulated Mmp1 expression cooperates with Ras to induce invasive tumors in *Drosophila*. *EMBO J.* 25, 5294-5304.
- Van Beveren C., van Straaten F., Curran T., Muller R. and Verma I.M. (1983). Analysis of FBJ-MuSV provirus and c-fos (mouse) gene

Fos in health and disease

- reveals that viral and cellular fos gene products have different carboxy termini. *Cell* 32, 1241-1255.
- Volm M., Drings P. and Wodrich W. (1993). Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. *J. Cancer Res. Clin. Oncol.* 119, 507-510.
- Wagner E.F. (2001). AP-1 reviews. *Oncogene* 20, 2333-2497.
- Wagner E.F. and Eferl R. (2005). Fos/AP-1 proteins in bone and the immune system. *Immunol. Rev.* 208, 126-140.
- Wagner E.F. and Matsuo K. (2003). Signalling in osteoclasts and the role of Fos/AP1 proteins. *Ann. Rheum. Dis.* 62 Suppl 2, ii83-85.
- Wang X., Xiao G., Zhang Y., Wen X., Gao X., Okada S. and Liu X. (2008). Regulation of Tcrb recombination ordering by c-Fos-dependent RAG deposition. *Nat. Immunol.* 9, 794-801.
- Wang X.J., Greenhalgh D.A., Donehower L.A. and Roop D.R. (2000). Cooperation between Ha-ras and fos or transforming growth factor alpha overcomes a paradoxical tumor-inhibitory effect of p53 loss in transgenic mouse epidermis. *Mol. Carcinog.* 29, 67-75.
- Wang X.J., Greenhalgh D.A., Lu X.R., Bickenbach J.R. and Roop D.R. (1995). TGF alpha and v-fos cooperation in transgenic mouse epidermis induces aberrant keratinocyte differentiation and stable, autonomous papillomas. *Oncogene* 10, 279-289.
- Wang Z.Q., Grigoriadis A.E., Mohle-Steinlein U. and Wagner E.F. (1991). A novel target cell for c-fos-induced oncogenesis: development of chondrogenic tumours in embryonic stem cell chimeras. *EMBO J.* 10, 2437-2450.
- Wang Z.Q., Liang J., Schellander K., Wagner E.F. and Grigoriadis A.E. (1995). c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. *Cancer Res.* 55, 6244-6251.
- Wang Z.Q., Ovitt C., Grigoriadis A.E., Mohle-Steinlein U., Ruther U. and Wagner E.F. (1992). Bone and haematopoietic defects in mice lacking c-fos. *Nature* 360, 741-745.
- Welsh J.B., Zarrinkar P.P., Sapinoso L.M., Kern S.G., Behling C.A., Monk B.J., Lockhart D.J., Burger R.A. and Hampton G.M. (2001). Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. *Proc. Natl. Acad. Sci. USA* 98, 1176-1181.
- Wicki A. and Christofori G. (2007). The potential role of podoplanin in tumour invasion. *Br. J. Cancer* 96, 1-5.
- Wicki A., Lehembre F., Wick N., Hantusch B., Kerjaschki D. and Christofori G. (2006). Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. *Cancer Cell* 9, 261-272.
- Yao D., Alexander C.L., Quinn J.A., Chan W.C., Wu H. and Greenhalgh D.A. (2008). Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity. *J. Cell Sci.* 121, 1758-1769.
- Yasoshima Y., Sako N., Senba E. and Yamamoto T. (2006). Acute suppression, but not chronic genetic deficiency, of c-fos gene expression impairs long-term memory in aversive taste learning. *Proc. Natl. Acad. Sci. USA* 103, 7106-7111.
- Young M.R., Li J.J., Rincon M., Flavell R.A., Sathyanarayana B.K., Hunziker R. and Colburn N. (1999). Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. *Proc. Natl. Acad. Sci. USA* 96, 9827-9832.
- Yuen M.F., Wu P.C., Lai V.C., Lau J.Y. and Lai C.L. (2001). Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. *Cancer* 91, 106-112.
- Zenz R., Eferl R., Scheinecker C., Redlich K., Smolen J., Schonhaler H.B., Kenner L., Tschachler E. and Wagner E.F. (2008). Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. *Arthritis Res. Ther.* 10, 201.
- Zhang J., McQuade J.M., Vorhees C.V. and Xu M. (2002a). Hippocampal expression of c-fos is not essential for spatial learning. *Synapse* 46, 91-99.
- Zhang J., Zhang D., McQuade J.S., Behbehani M., Tsien J.Z. and Xu M. (2002b). c-fos regulates neuronal excitability and survival. *Nat. Genet.* 30, 416-420.

Accepted April 20, 2009